Gabriele Gamerith

1.9k total citations
44 papers, 914 citations indexed

About

Gabriele Gamerith is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Gabriele Gamerith has authored 44 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Gabriele Gamerith's work include Cancer Cells and Metastasis (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Immunotherapy and Immune Responses (7 papers). Gabriele Gamerith is often cited by papers focused on Cancer Cells and Metastasis (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Immunotherapy and Immune Responses (7 papers). Gabriele Gamerith collaborates with scholars based in Austria, Netherlands and United Kingdom. Gabriele Gamerith's co-authors include Arno Amann, H. Zwierzina, Wolfgang Hilbe, Andreas Kronbichler, Hans van Vliet, Jae Il Shin, Julia Huber, Jong Yeob Kim, Sung Hwi Hong and Michael Eisenhut and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Gabriele Gamerith

43 papers receiving 899 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gabriele Gamerith Austria 18 507 233 200 193 179 44 914
Dalong Wan China 12 439 0.9× 280 1.2× 240 1.2× 162 0.8× 173 1.0× 30 1.1k
Shan M. Chin United States 7 341 0.7× 249 1.1× 84 0.4× 148 0.8× 110 0.6× 13 649
Michitaka Nakano Japan 14 527 1.0× 198 0.8× 90 0.5× 118 0.6× 122 0.7× 33 764
Anna-Maria Larsson Sweden 14 480 0.9× 232 1.0× 135 0.7× 345 1.8× 71 0.4× 27 859
Françoise Drusch France 14 544 1.1× 215 0.9× 195 1.0× 305 1.6× 123 0.7× 17 924
Karwan Moutasim United Kingdom 17 455 0.9× 440 1.9× 193 1.0× 275 1.4× 44 0.2× 35 1.0k
Michele Iuliani Italy 18 429 0.8× 350 1.5× 285 1.4× 271 1.4× 58 0.3× 39 947
Cristina Nieto‐Jiménez Spain 16 464 0.9× 456 2.0× 139 0.7× 137 0.7× 64 0.4× 40 942
Rekha Samuel United States 9 261 0.5× 280 1.2× 67 0.3× 162 0.8× 114 0.6× 9 706
Tatsuya Manabe Japan 18 544 1.1× 245 1.1× 157 0.8× 153 0.8× 87 0.5× 63 1.0k

Countries citing papers authored by Gabriele Gamerith

Since Specialization
Citations

This map shows the geographic impact of Gabriele Gamerith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriele Gamerith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriele Gamerith more than expected).

Fields of papers citing papers by Gabriele Gamerith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriele Gamerith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriele Gamerith. The network helps show where Gabriele Gamerith may publish in the future.

Co-authorship network of co-authors of Gabriele Gamerith

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriele Gamerith. A scholar is included among the top collaborators of Gabriele Gamerith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriele Gamerith. Gabriele Gamerith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fuereder, Thorsten, Konrad Klinghammer, Birgit Grünberger, et al.. (2024). 880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial. Annals of Oncology. 35. S629–S629. 2 indexed citations
2.
Magnes, Teresa, Thomas Melchardt, Lukas Weiß, et al.. (2023). Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer. Anticancer Research. 43(3). 1273–1282. 4 indexed citations
3.
Gamerith, Gabriele, Peter A. Merkel, Kristina M. Harris, et al.. (2022). Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Annals of the Rheumatic Diseases. 82(2). 253–261. 18 indexed citations
4.
Sopper, Sieghart, Arno Amann, Andreas Pircher, et al.. (2020). Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology. 153. 102948–102948. 21 indexed citations
5.
Gamerith, Gabriele, Florian Kocher, Jakob Rudzki, & Andreas Pircher. (2018). ASCO 2018 NSCLC highlights—combination therapy is key. memo - Magazine of European Medical Oncology. 11(4). 266–271. 12 indexed citations
6.
Klepsch, Victoria, Natascha Hermann‐Kleiter, Bojana Jakic, et al.. (2018). Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nature Communications. 9(1). 1538–1538. 52 indexed citations
7.
Gamerith, Gabriele, Hubert Hackl, Jeffrey C. Kern, et al.. (2018). Soluble immune checkpoints CD27, Lag3, PD-L2 and Tim3 in early stage NSCLC patients. European Journal of Cancer. 92. S12–S12. 1 indexed citations
8.
Amann, Arno, Marit Zwierzina, Gabriele Gamerith, et al.. (2017). Development of a 3D angiogenesis model to study tumour – endothelial cell interactions and the effects of anti-angiogenic drugs. Scientific Reports. 7(1). 2963–2963. 53 indexed citations
9.
Zwierzina, Marit, Gabriele Gamerith, Edith Lorenz, et al.. (2017). The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3+CD8+ tumor infiltrating lymphocyte subpopulations. OncoImmunology. 6(6). e1323617–e1323617. 19 indexed citations
10.
Zwierzina, Marit, Julia Huber, Mario Bitsche, et al.. (2016). Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers. Immunobiology. 221(5). 604–617. 6 indexed citations
11.
Huber, Julia, Arno Amann, Edith Lorenz, et al.. (2016). Evaluation of assays for drug efficacy in a three-dimensional model of the lung. Journal of Cancer Research and Clinical Oncology. 142(9). 1955–1966. 33 indexed citations
12.
13.
Newsom-Davis, Thomas, Rossana Berardi, Linda Coate, et al.. (2015). Emergency diagnosis of lung cancer: An international problem.. Journal of Clinical Oncology. 33(15_suppl). 6536–6536. 4 indexed citations
14.
Gamerith, Gabriele, Johannes Rainer, Arno Amann, et al.. (2015). Abstract 326: Differences in RNA expression and chemosensitivity in 2D versus 3D non-small-cell lung cancer cultures. Cancer Research. 75(15_Supplement). 326–326. 1 indexed citations
15.
Mian, Michael, Gabriele Gamerith, Patrizia Mondello, et al.. (2014). R-CHOP versus R-COMP: Are They Really Equally Effective?. Clinical Oncology. 26(10). 648–652. 11 indexed citations
16.
Fiegl, Michael, Andreas Pircher, Gabriele Gamerith, et al.. (2014). Small steps of improvement in small-cell lung cancer (SCLC) within two decades: A comprehensive analysis of 484 patients. Lung Cancer. 84(2). 168–174. 23 indexed citations
17.
Amann, Arno, Marit Zwierzina, Gabriele Gamerith, et al.. (2014). Development of an Innovative 3D Cell Culture System to Study Tumour - Stroma Interactions in Non-Small Cell Lung Cancer Cells. PLoS ONE. 9(3). e92511–e92511. 130 indexed citations
18.
Pircher, Andreas, Gabriele Gamerith, Arno Amann, et al.. (2014). Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 85(1). 81–87. 44 indexed citations
19.
Gamerith, Gabriele, T. Auer, Arno Amann, et al.. (2013). Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. Cancer Biology & Therapy. 15(3). 266–270. 7 indexed citations
20.
Schmitz, Klaus J., Georgios C. Sotiropoulos, Hideo A. Baba, et al.. (2011). AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver International. 31(6). 810–816. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dalong Wan Breakdown of academic impact, for papers by Shan M. Chin Breakdown of academic impact, for papers by Michitaka Nakano Breakdown of academic impact, for papers by Anna-Maria Larsson Breakdown of academic impact, for papers by Françoise Drusch Breakdown of academic impact, for papers by Karwan Moutasim Breakdown of academic impact, for papers by Michele Iuliani Breakdown of academic impact, for papers by Cristina Nieto‐Jiménez Breakdown of academic impact, for papers by Rekha Samuel Breakdown of academic impact, for papers by Tatsuya Manabe
Rankless by CCL
2026